tiprankstipranks
Rapid Therapeutic Science Laboratories (RTSL)
OTHER OTC:RTSL
US Market
RTSL
Rapid Therapeutic Science Laboratories
RESEARCH TOOLSreports

Rapid Therapeutic Science Laboratories (RTSL) Financial Statements

29 Followers

Rapid Therapeutic Science Laboratories Financial Overview

Rapid Therapeutic Science Laboratories's market cap is currently ―. The company's EPS TTM is $-0.015; its P/E ratio is -0.70; Rapid Therapeutic Science Laboratories is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue---$ 0.00$ 0.00
Gross Profit---$ 0.00$ 0.00
EBIT$ 107.25K$ 302.30K$ 97.92K$ 119.09K$ 728.75K
EBITDA$ 155.76K$ 338.62K$ -7.81K$ 146.35K$ 756.00K
Net Income Common Stockholders$ 46.42K$ 966.99K$ 3.36M$ -227.08K$ -36.84K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.16K$ 17.57K$ 0.00$ 0.00$ 112.16K
Total Assets$ 2.07M$ 2.03M$ 2.25M$ 2.29M$ 2.43M
Total Debt$ 3.79M$ 3.78M$ 3.83M$ 3.78M$ 3.50M
Net Debt$ 3.78M$ 3.76M$ 3.83M$ 3.78M$ 3.39M
Total Liabilities$ 4.81M$ 4.87M$ 5.40M$ 5.37M$ 5.35M
Stockholders Equity$ -2.74M$ -2.84M$ -3.14M$ -3.09M$ -2.92M
Cash Flow-
Free Cash Flow$ -7.33K$ -41.81K$ -36.40K$ -165.41K$ -254.42K
Operating Cash Flow$ -7.33K$ -41.81K$ -352.05K$ -165.41K$ -250.47K
Investing Cash Flow--$ 315.65K$ -1.00$ -3.95K
Financing Cash Flow$ -8.09K$ 59.39K$ 36.40K$ 53.25K$ 333.60K
Currency in USD

Rapid Therapeutic Science Laboratories Earnings and Revenue History

Rapid Therapeutic Science Laboratories Debt to Assets

Rapid Therapeutic Science Laboratories Cash Flow

Rapid Therapeutic Science Laboratories Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis